EntreMed Hopes To Partner, Rapidly Advance Promising Kinase Inhibitor
This article was originally published in The Pink Sheet Daily
Executive Summary
With no revenue for first half of 2008, finding a partner is crucial to development of EMND-2076.
You may also be interested in...
Troubled Biotechs: Adventrx, EntreMed, Peregrine, Anesiva
Adventrx enacts second staff reduction to continue operations as top two candidates near FDA filing.
Troubled Biotechs: Adventrx, EntreMed, Peregrine, Anesiva
Adventrx enacts second staff reduction to continue operations as top two candidates near FDA filing.
EntreMed Panzem To Boost Bioavailability Under Elan Supply Deal
Elan will reformulate and manufacture Panzem (2-methoxyestradiol) as an oral liquid formulation using its NanoCrystal technology. EntreMed expects to initiate a clinical oncology program in 2005 using the new formulation.